BIO-TECHNE Corp
TECHNasdaq · SIC 2836
$72.12
↑ +0.5%Jul 17 close · end-of-day
Price
1Y↑ +40.1%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$11.4B
Enterprise Value
$11.3B
P/E
104.5
P/S
9.4
P/B
5.4
EV/EBITDA
44.6
PEG
—
FCF Yield
2.4%
Dividend Yield
0.4%
Revenue (TTM)
$1.2B
Net Income (TTM)
$109.6M
Free Cash Flow (TTM)
$269.6M
Gross Margin
65.0%
Operating Margin
12.7%
Net Margin
9.0%
ROE
5.3%
ROIC
5.5%
Debt / Equity
0.1
Net Cash
$9.8M
Return 1Y
+36.1%
Company profile
Bio-Techne Corporation develops, manufactures, and sells life science reagents, instruments, and services. Protein Sciences segment provides biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy. Diagnostics and Genomics segment provides diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market.
- CEO
- Charles R. Kummeth
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 3,000
- Headquarters
- Minnesota
- Website
- bio-techne.com
Management & directors
- Crouse Steven C.President - Diag & Spatial Bi
- Bohnen ShaneSVP - General Counsel
- Hippel JamesCFO
- Kelderman KimChief Executive Officer
Roles derived from SEC Form 4 filings.
Earnings
Next earnings · estimated2026-08-05
TECH Q3 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$311.4M↓ -1.5%
Diluted EPS$0.32↑ +128.6%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $931.0M | $1.1B | $1.1B | $1.2B | $1.2B |
| Gross profit | $632.9M | $756.5M | $769.8M | $769.7M | $790.3M |
| Operating income | $237.3M | $296.6M | $298.9M | $206.7M | $102.3M |
| Net income | $140.4M | $272.1M | $285.3M | $168.1M | $73.4M |
| Diluted EPS | $0.87 | $1.66 | $1.76 | $1.05 | $0.46 |
| Operating cash flow | $352.2M | $325.3M | $254.4M | $299.0M | $287.6M |
| Free cash flow | $307.9M | $280.4M | $216.1M | $236.1M | $256.6M |
| Gross margin | 68.0% | 68.4% | 67.7% | 66.4% | 64.8% |
| Operating margin | 25.5% | 26.8% | 26.3% | 17.8% | 8.4% |
| Net margin | 15.1% | 24.6% | 25.1% | 14.5% | 6.0% |
| Line item | Q4 '24 | Q1 '24 | Q2 '24 | Q3 '25 | Q4 '25 | Q1 '25 | Q2 '25 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $306.1M | $289.5M | $297.0M | $316.2M | $317.0M | $286.6M | $295.9M | $311.4M |
| Gross profit | $203.3M | $183.0M | $193.9M | $214.6M | $198.8M | $188.1M | $191.3M | $208.3M |
| Operating income | $45.8M | $40.0M | $47.4M | $38.7M | -$23.9M | $47.7M | $54.5M | $75.5M |
| Net income | $40.6M | $33.6M | $34.9M | $22.6M | -$17.7M | $38.2M | $38.0M | $51.0M |
| Diluted EPS | $0.26 | $0.21 | $0.22 | $0.14 | -$0.11 | $0.24 | $0.24 | $0.32 |
| Operating cash flow | $75.5M | $63.9M | $84.3M | $41.1M | $98.2M | $27.6M | $82.4M | $86.7M |
| Free cash flow | $57.5M | $54.7M | $77.5M | $31.0M | $93.3M | $22.2M | $76.5M | $77.6M |
| Gross margin | 66.4% | 63.2% | 65.3% | 67.9% | 62.7% | 65.6% | 64.6% | 66.9% |
| Operating margin | 15.0% | 13.8% | 16.0% | 12.2% | -7.5% | 16.6% | 18.4% | 24.2% |
| Net margin | 13.3% | 11.6% | 11.7% | 7.1% | -5.6% | 13.3% | 12.8% | 16.4% |
Company news
Jun 29, 2026
Jun 26, 2026
- 24d agoThe $11 Billion Reason TECH Stock Is Up Todaybarchart.com
- 24d agoMerck KGaA to acquire Bio-Techne in $11.3 billion dealqz.com
- 24d agoCompany News for Jun 26, 2026finance.yahoo.com
- 24d agoBio-Techne (TECH) Agrees To $11.5 Billion Merck KGaA Buyoutfinance.yahoo.com
- 24d agoGermany’s Merck Pumps Up Life Sciences Biz with $11.3B Bio-Techne Dealthedailyupside.com
- 24d agoBio-Techne (TECH) Soars 20% on Merck $11.3B Mergerfinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-02 | Crouse Steven C.· President - Diag & Spatial Bi | Tax withholding | 216 | $49.77 | $10,750.32 | filing |
| 2026-06-02 | Crouse Steven C.· President - Diag & Spatial Bi | Option exercise | 600 | — | — | filing |
| 2026-05-08 | Herr Amy E. | Sale | 6,636 | $48.28 | $320,386.08 | filing |
| 2026-05-08 | Herr Amy E. | Option exercise | 6,636 | $47.60 | $315,873.60 | filing |
| 2026-05-05 | Hippel James· CFO | Tax withholding | 56,955 | $56.68 | $3.2M | filing |
| 2026-05-05 | Hippel James· CFO | Option exercise | 62,000 | $47.60 | $3.0M | filing |
| 2026-05-05 | Kelderman Kim· Chief Executive Officer | Tax withholding | 23,951 | $56.68 | $1.4M | filing |
| 2026-05-05 | Kelderman Kim· Chief Executive Officer | Option exercise | 26,692 | $47.60 | $1.3M | filing |
| 2026-05-05 | Bohnen Shane· SVP - General Counsel | Tax withholding | 7,055 | $56.68 | $399,877.40 | filing |
| 2026-05-05 | Bohnen Shane· SVP - General Counsel | Option exercise | 8,400 | $47.60 | $399,840.00 | filing |
| 2026-05-01 | Crouse Steven C.· President - Diag & Spatial Bi | Tax withholding | 311 | $55.02 | $17,111.22 | filing |
| 2026-05-01 | Crouse Steven C.· President - Diag & Spatial Bi | Option exercise | 794 | — | — | filing |
| 2026-04-22 | Hippel James· CFO | Tax withholding | 56,097 | $58.58 | $3.3M | filing |
| 2026-04-22 | Kelderman Kim· Chief Executive Officer | Tax withholding | 1,363 | $58.58 | $79,844.54 | filing |
| 2026-04-22 | Hippel James· CFO | Option exercise | 62,000 | $0.00 | $0.00 | filing |
| 2026-04-22 | Kelderman Kim· Chief Executive Officer | Option exercise | 11,344 | $0.00 | $0.00 | filing |
| 2026-04-14 | Kelderman Kim· Chief Executive Officer | Tax withholding | 32,088 | $58.66 | $1.9M | filing |
| 2026-04-14 | Kelderman Kim· Chief Executive Officer | Option exercise | 36,500 | $0.00 | $0.00 | filing |
| 2026-04-03 | Bohnen Shane· SVP - General Counsel | Tax withholding | 740 | $53.13 | $39,316.20 | filing |
| 2026-04-03 | Bohnen Shane· SVP - General Counsel | Option exercise | 2,259 | $0.00 | $0.00 | filing |
| 2026-02-17 | Herr Amy E. | Sale | 1,976 | $59.11 | $116,791.48 | filing |
Latest 21 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.